# BlueWillow Biologics

**Canonical:** https://apis.io/providers/bluewillow-biologics/  
**Website:** https://bluewillow.com/  
**APIs profiled:** 1

BlueWillow Biologics is a clinical‑stage biotechnology company pioneering intranasal vaccine technology. Their NanoVax® platform delivers antigens via an oil‑in‑water emulsion, aiming to transform prevention and treatment of infectious diseases, pandemic preparedness, and food allergies. The company originated from University of Michigan research and now advances human clinical trials of its adjuvant and delivery system.

## Kin Score — 4.8 / 100 (minimal)

Scored 2026-10-23 under rubric 0.25.0. Trend: flat (+0.0 from 4.8).

| Facet | Score |
|---|---|
| Discoverability | 58.9 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 4.7 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |

## APIs (1)

- **BlueWillow Biologics API** — API documentation not publicly available; no machine-readable contract discovered.

## Security (1)

- **Bluewillow Biologics Domain Security** — TLSv1.3 · HSTS

## Tags

Biotechnology, Intranasal Vaccines, Clinical Stage, Nanotechnology, Health, Company

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/bluewillow-biologics/). Scores are computed from the provider's own public artifacts under a published rubric.